Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

[18F]MNI-1126

Method of Measurement (Pre-analytical Tools)
Imaging
Biomarker Measured
Neuronal damage
Use
Monitoring
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

To examine [18F]MNI-1126 as a tool to assess synaptic density loss. The specific objectives are: Examine [18F]MNI-1126 as a tool to assess synaptic density loss. To measure the dynamic uptake and washout of [18F]MNI-1126 in the brain using positron emission tomography (PET) in subjects with AD, PD, and healthy volunteers. To measure blood metabolites of [18F]MNI-1126 and perform kinetic modeling to assess its ability to measure synaptic density loss in the brain using the tracer plasma concentration or a reference region as indirect input. To acquire safety data following injection of [18F]MNI-1126.

Target Population/ Population Being Studied

Subjects with AD, PD, and healthy volunteers

Length of Current Trial
1 year
Number of Trial Participants

15

Estimated Trial Completion
May 2020
What is Required from Patients

injection of radioactive tracers, mild discomfort, in clinic visit

What is Required from the Health System

PET technician, PET scanner, dyes

Sponsor

Invicro

“Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss.” ClinicalTrials.gov. Accessed October 8, 2019. https://clinicaltrials.gov/ct2/show/NCT03587649?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=5&rank=41